Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis.
Krismer F, Seppi K, Jönsson L, Åström DO, Berger AK, Simonsen J, Gordon MF, Wenning GK, Poewe W; European Multiple System Atrophy Study Group Natural History Study Investigators; Rasagiline-for-Multiple System Atrophy Investigators. Krismer F, et al. Among authors: gordon mf. Mov Disord. 2022 Jul;37(7):1425-1431. doi: 10.1002/mds.28993. Epub 2022 Mar 25. Mov Disord. 2022. PMID: 35332582 Free PMC article.
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Harary E, Alexander J, Barkay H, Gordon MF. Jankovic J, et al. Among authors: gordon mf. Mov Disord Clin Pract. 2023 Aug 24;10(9):1388-1398. doi: 10.1002/mdc3.13849. eCollection 2023 Sep. Mov Disord Clin Pract. 2023. PMID: 37772282 Free PMC article.
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Hauser RA, Barkay H, Fernandez HH, Jimenez-Shahed J, Factor SA, Gross N, Marinelli L, Gordon MF, Barash S, Finkbeiner S, Chaijale N, Anderson KE. Hauser RA, et al. Among authors: gordon mf. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21. J Clin Psychopharmacol. 2024. PMID: 38901008
Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: gordon mf. Neurol Ther. 2024 Dec;13(6):1747-1749. doi: 10.1007/s40120-024-00660-3. Neurol Ther. 2024. PMID: 39266813 Free PMC article. No abstract available.
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: gordon mf. Neurol Ther. 2024 Jun;13(3):655-675. doi: 10.1007/s40120-024-00600-1. Epub 2024 Apr 1. Neurol Ther. 2024. PMID: 38557959 Free PMC article.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Among authors: gordon mf. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod.
Roussakis AA, Gennaro M, Gordon MF, Reilmann R, Borowsky B, Rynkowski G, Lao-Kaim NP, Papoutsou Z, Savola JM, Hayden MR, Owen DR, Kalk N, Lingford-Hughes A, Gunn RN, Searle G, Tabrizi SJ, Piccini P. Roussakis AA, et al. Among authors: gordon mf. Brain Commun. 2023 Apr 3;5(2):fcad084. doi: 10.1093/braincomms/fcad084. eCollection 2023. Brain Commun. 2023. PMID: 37020532 Free PMC article.
104 results